Importantly, studies on glioblastoma, metastatic melanoma [151], breast cancer [152], and prostate cancer [142] have confirmed that exosomal PD-L1 can mediate resistance to immunotherapy by directly binding to an anti-PD-L1 antibody [153]. Here, CD274 is linked to breast carcinoma.